SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
Investigated for use/treatment in neurologic disorders.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.